Experiments performed in bone-conditioned media suggest that in addition to enhancing viability, locally produced estrogen also sustains ER+ breast cancer cell proliferation, and that aromatase inhibitors directly modulate this axis. The gene discussed is CYP19A1; the disease is breast cancer.